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Summary
Activated RAS promotes dimerization of members of the RAF kinase family1-3. ATP-competitive 
RAF inhibitors activate ERK signaling4-7 by transactivating RAF dimers4. In melanomas with 
mutant BRAF(V600E), levels of RAS activation are low and these drugs bind to BRAF(V600E) 
monomers and inhibit their activity. This tumor-specific inhibition of ERK signaling results in a 
broad therapeutic index and RAF inhibitors have remarkable clinical activity in patients with 
melanomas that harbor mutant BRAF(V600E)8. However, resistance invariably develops. Here, 
we identify a novel resistance mechanism. We find that a subset of cells resistant to vemurafenib 
(PLX4032, RG7204) express a 61kd variant form of BRAF(V600E) that lacks exons 4-8, a region 
that encompasses the RAS-binding domain. p61BRAF(V600E) exhibits enhanced dimerization in 
cells with low levels of RAS activation, as compared to full length BRAF(V600E). In cells in 
which p61BRAF(V600E) is expressed endogenously or ectopically, ERK signaling is resistant to 
the RAF inhibitor. Moreover, a mutation that abolishes the dimerization of p61BRAF(V600E) 
restores its sensitivity to vemurafenib. Finally, we identified BRAF(V600E) splicing variants 
lacking the RAS-binding domain in the tumors of six of 19 patients with acquired resistance to 
vemurafenib. These data support the model that inhibition of ERK signaling by RAF inhibitors is 
dependent on levels of RAS-GTP too low to support RAF dimerization and identify a novel 
mechanism of acquired resistance in patients: expression of splicing isoforms of BRAF(V600E) 
that dimerize in a RAS-independent manner.
RAF inhibitors have remarkable clinical activity in mutant BRAF melanomas that is limited 
by acquisition of drug resistance8. To identify novel mechanisms of resistance, we generated 
cell lines resistant to vemurafenib by exposing the BRAF-mutant (V600E) melanoma cell 
line SKMEL-239 to a high dose of drug (2μM). At this concentration, vemurafenib 
effectively inhibited ERK signaling and induced cell cycle arrest and cell death (Fig. 1a-c, 
Supplementary Fig. 2a and data not shown (DNS)). Five independent vemurafenib-resistant 
cell populations were generated after approximately 2 months of continuous drug exposure 
(Fig. 1a). We chose this approach rather than one of gradual adaptation to increasing 
concentrations of drug since it more closely represents the clinical situation8.
Resistance of SKMEL-239 cells to vemurafenib was associated with decreased sensitivity of 
ERK signaling to the drug (Fig. 1b, c, Supplementary Fig. 2b). Analysis revealed the 
presence of two distinct classes of resistant clones. In the first, exemplified by the C3 clone, 
the IC50 for pMEK inhibition was more than 100-fold higher than that of the parental cell 
line (Fig. 1d, e). Despite a similar degree of resistance to the anti-proliferative and pro-
apoptotic effects of the drug, the second class of clones, exemplified by clone C5, 
demonstrated only a modest increase in pMEK IC50 (4.5-fold higher than the parental cell 
line). All five resistant clones retained sensitivity to the MEK inhibitor PD03259019, albeit 
at slightly higher doses (Supplementary Fig. 3a, b).
Analysis of DNA and cDNA derived from the five resistant clones showed that all retained 
expression of BRAF(V600E) (Supplementary Fig. 4a, b). We did not detect mutation in 
BRAF at the gatekeeper site10, RAS mutation, upregulation of receptor tyrosine kinase 
activity or COT overexpression (Supplementary Fig. 5a, b and DNS). Analysis of BRAF 
protein expression showed that each of the resistant clones expressed a 90kd band that co-
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migrated with the band observed in parental cells. In the C1, C3 and C4 clones, a new band 
was also identified, at an approximate molecular weight of 61kd (p61BRAF(V600E), Fig. 
1c, Supplementary Fig. 2b). No band of this size was detected in parental SKMEL-239 cells 
or in a panel of 22 other melanoma cell lines (Supplementary Fig. 6).
PCR analysis of cDNA revealed the expected single transcript of 2.3kb, representing full-
length BRAF in parental cells and two transcripts of 2.3kb and 1.7kb in C3 cells. The 1.7kb 
product was a BRAF transcript that contained the V600E mutation and an in-frame deletion 
of exons 4-8 (Fig. 2a and Supplementary Fig. 7). This 1.7kb transcript is predicted to encode 
a protein of 554 amino acids (M.W. 61kd), consistent with the lower BRAF band detected 
by immunoblotting. Exons 4-8 include domains critical for RAF activation, most notably, 
the RAS-binding domain (RBD) and the cysteine-rich domain (CRD)3. Analogous deletions 
in wild-type BRAF and CRAF promote RAF dimerization and render RAS activity 
dispensable for this process1,4. The 61kd BRAF variant identified in C3 was also detected in 
clones C1 and C4 by qPCR, with a primer that anneals specifically to the exons 3/9 junction 
(Supplementary Fig. 8). Inspection of the BRAF locus on chromosome 7q34 by array CGH 
data suggested no evidence of an intragenic somatic deletion within the BRAF gene.
The 1.7kb transcript was cloned into an expression vector and expressed in 293H cells, 
alone or together with full-length wild-type BRAF. ERK signaling was resistant to 
vemurafenib when p61BRAF(V600E) was ectopically expressed (Fig 2b). Expression of 
p61BRAF(V600E) in parental SKMEL-239 cells or in HT-29 (BRAF(V600E)) cells also 
resulted in failure of vemurafenib to effectively inhibit ERK signaling (Supplementary Fig. 
9a, b). To test whether ERK signaling in C3 cells was dependent on p61BRAF(V600E), we 
designed siRNAs directed against either the 3/9 splice junction or a region within the exon 
4-8 deletion to selectively suppress the expression of p61BRAF(V600E) or full-length 
BRAF, respectively. In parental cells, ERK signaling was inhibited by knockdown of full-
length BRAF(V600E) (Supplementary Fig. 10a). In C3 cells, phosphorylation of MEK, 
cyclin D1 expression and cell growth were inhibited upon knockdown of p61BRAF(V600E) 
but not of full-length wild type BRAF, ARAF or CRAF (Supplementary Fig. 10b, c). 
Moreover, in C3 cells in which the expression of full-length BRAF or CRAF was knocked 
down, ERK signaling remained resistant to vemurafenib (Supplementary Fig. 10d).
Vemurafenib inhibits the kinase activity of RAF immunoprecipitated from cells, but 
activates intracellular RAF in BRAF wild-type cells4. This suggests that the conditions 
required for transactivation in vivo are not recapitulated in the in vitro assay. We tested 
whether p61BRAF(V600E) is also sensitive to this inhibitor in vitro. Although the in vitro 
activity of p61BRAF(V600E) was slightly higher than full-length BRAF(V600E), similar 
concentrations of vemurafenib caused their inhibition in vitro (Supplementary Fig. 11). 
These data indicate that resistance of p61BRAF(V600E) to vemurafenib is not due to its 
inability to bind the inhibitor.
It has been shown that the N-terminus of RAF negatively regulates the C-terminal catalytic 
domain11 and that truncation of the N-terminus results in constitutive dimerization of the 
protein in the absence of activated RAS1. To ask whether deletion of exons 4-8 promotes 
dimerization of p61BRAF(V600E), we co-expressed two constructs encoding the same 
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protein (either p61BRAF(V600E) or full-length BRAF(V600E)) but with different tags 
(Flag or V5) and then immunoblotted for V5 after immunoprecipating FLAG. As shown in 
Fig. 2c, dimerization of p61BRAF(V600E) was significantly elevated compared to that of 
full-length BRAF(V600E). The R509 residue is within the BRAF dimerization interface. 
Mutation of this residue to a histidine significantly diminishes dimerization of wild-type 
BRAF and results in loss of its catalytic activity in cells4,12. However, full length 
BRAF(V600E/R509H) expressed in 293H cells retained its ability to fully activate ERK 
signaling and remained sensitive to vemurafenib (Fig. 2d). Moreover, BRAF(V600E/
R509H) fully activated ERK signaling when expressed in either BRAF-null or ARAF/
CRAF-null MEFs (Supplementary Fig. 12a, b). These results show that, in contrast to wild-
type BRAF, BRAF(V600E) can signal as a monomer and that active RAS and dimerization 
are not necessary for its activation.
Our model implies that, in tumors with BRAF(V600E), elevation of RAS-GTP or alterations 
that cause increased RAF dimerization in the absence of RAS activation will confer 
resistance to RAF inhibitors4,13. To test whether resistance mediated by p61BRAF(V600E) 
was the result of elevated dimer formation, we introduced the R509H dimerization-deficient 
mutation into p61BRAF(V600E). In 293H cells expressing p61BRAF(V600E), 
phosphorylation of ERK was elevated and was insensitive to vemurafenib (Fig. 2e). ERK 
activity was also elevated in cells expressing p61BRAF(V600E/R509H), but to a slightly 
lesser degree. p61BRAF(V600E/R509H) showed impaired dimerization, confirming that the 
R509H mutation located within the dimerization interface disrupts the formation of 
p61RAF(V600E) dimers (Fig. 2c and Supplementary Figure 13). Finally, this monomeric 
p61BRAF(V600E/R509H) was sensitive to RAF inhibitors; in cells ectopically expressing 
this mutant, ERK signaling was inhibited by vemurafenib (Fig. 2e). Thus, the R509H 
mutation by impairing dimerization of p61BRAF(V600E) restores sensitivity to the RAF 
inhibitor.
To determine whether BRAF variants can account for clinical resistance to RAF inhibitors, 
we analyzed tumors from nineteen melanoma patients with acquired resistance to 
vemurafenib. PCR analysis of cDNA from pre-treatment samples showed a single band of 
the expected size (2.3kb) which was sequenced and confirmed to include both 
BRAF(V600E) and wild-type BRAF transcripts (Fig. 3A, B and DNS). We identified two 
PCR products in six of the post-treatment progression samples, including three with 
matching pre-treatment samples. The shorter PCR products encoded BRAF(V600E) 
transcripts lacking exons 4-10 (pt 1), exons 4-8, (pt 11, identical to the variant identified in 
the resistant cell lines), exons 2-8 (pt 12), or exons 2-10 (pts 5, 6 and 19) (Fig. 3a-c, 
Supplementary Table 1). Mutations in NRAS, were identified in 4 of 19 progression samples 
and were found to be mutually exclusive with BRAF splicing variants. BRAF splicing 
variants were not detected in two samples derived from patients with intrinsic resistance (pt 
20 shown) or in 27 additional melanomas resected from vemurafenib-naïve patients (Fig. 3a, 
Supplementary Table 1 and DNS). Finally, we did not detect significant levels of BRAF 
splicing variants in melanoma cell lines and tumors that have not been exposed to RAF 
inhibitors. However, the assay employed cannot exclude the possibility that such variants 
may be expressed in small amounts prior to drug selection and subsequently selected under 
conditions of continuous treatment with the drug.
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In tumors from patients that have been analyzed, resistance to vemurafenib is frequently 
associated with inability of the drug to inhibit ERK signaling14. Our model suggests that this 
can be due to increased RAF dimer formation in the cell4. This can happen in at least two 
ways: increasing RAS-GTP levels and induction of RAS-independent dimerization 
(Supplementary Figure 1a, b). NRAS mutation has recently been reported in resistant 
tumors15. Other mechanisms of resistance to RAF inhibitors in model systems and in 
patients have also been reported, including activation of receptor tyrosine kinases, COT 
overexpression and MEK1 mutation 15-18. We now report a lesion in patient tumors that 
results in RAF inhibitor resistance by inducing increased, RAS-independent dimerization.
Expression of BRAF(V600E) splicing variants is the first resistance mechanism identified 
that involves a structural change in BRAF. In each case, the alternative splicing forms 
identified in the cell lines and patients were in frame and confined to the mutant BRAF 
allele. This suggests that generation of the splicing variants is likely due to a mutation or 
epigenetic change that affects BRAF splicing and not to a loss of global splicing fidelity19. 
The identification of BRAF variants lacking the RAS-binding domain in six of nineteen 
patients with acquired resistance suggests that this mechanism is clinically important. 
Acquired resistance mediated by BRAF(V600E) splicing variants is due to insensitivity of 
the enzyme to RAF inhibitors. These tumors should retain sensitivity to inhibitors of 
downstream components of the pathway such as MEK, which was indeed the case 
(Supplementary Fig. 3). Therefore, MEK inhibitors used in combination with vemurafenib 
could delay or prevent resistance by this mechanism.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
Methods
Compounds
Vemurafenib (PLX4032) was obtained from Plexxikon Inc. PD0325901 was synthesized in 
the MSKCC Organic Synthesis Core Facility by O. Ouerfelli. Drugs were dissolved in 
DMSO and stored at −20°C.
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Cell proliferation and cell cycle analysis
All melanoma cell lines were generated by A. Houghton (MSKCC) or obtained from ATCC. 
293H cells were obtained from Invitrogen. Cells were maintained in DMEM (293H and 
MEFs), or RPMI (all other cell lines) supplemented with 2mM glutamine, antibiotics and 
10% fetal bovine serum. We confirmed by DNA fingerprinting21 that all PLX4032-resistant, 
SKMEL-239 clones were derived from the same patient, thus excluding the possibility of 
cross contamination (Supplemental Table 2). For proliferation assays, cells were plated in 6 
well plates and 24 hours later were treated with varying concentrations of inhibitors as 
indicated. IC50 values were calculated using Graph Pad Prism v.5. For cell cycle and 
apoptosis studies, cells were seeded in 6 well dishes the day prior to drug treatment. For 
analysis, both adherent and floating cells were harvested and stained with ethidium bromide 
as described previously 22.
Western blotting and receptor tyrosine kinase (RTK) arrays
Western blot analysis was performed as previously described9. The following antibodies 
were used: p217/p221-MEK (pMEK), p202/p204-ERK (pERK), p338CRAF, p473AKT, 
MEK (Cell Signaling), V5 tag (Invitrogen), ARAF, BRAF, cyclin D1, p27, COT (Santa 
Cruz), CRAF (BD Biosciences), Flag tag, β-actin (Sigma). For immunoprecipitations of 
tagged proteins: anti-Flag M2 affinity gel (Sigma). The Human Phospho-RTK array Kit 
(R&D Systems) was utilized to detect kinase activation within a panel of RTKs. Briefly, 
cells were plated in 10 cm dishes and harvested after 24 hours. Following lysis, 500 μg of 
lysate was applied to a membrane-anchored RTK array and incubated at 4°C for 24 hours. 
Membranes were exposed to chemiluminescent reagents and images captured using the 
ImageQuant LAS 4000 instrument (GE HealthCare).
Plasmids/Trasfections
Flag-tagged BRAF constructs have been described previously4. All other plasmids were 
created using standard cloning methods, with pcDNA3.1 (Invitrogen) as a vector. Mutations 
were introduced using the site-directed Mutagenesis Kit (Stratagene). For transfection 
studies, cells were seeded into 35mm or 100mm plates and transfected the following day 
using Lipofectamine 2000 (Invitrogen). Cells were collected 24 hours later for subsequent 
analysis.
Immunoprecipitations and kinase assays
Cells were lysed in lysis buffer (50mM Tris, pH7.5, 1% NP40, 150mM NaCl, 10% glycerol, 
1mM EDTA) supplemented with protease and phosphatase inhibitor cocktail tablets 
(Roche). Immunoprecipitations were performed at 4°C for 4h, followed by three washes 
with lysis buffer and, in cases of subsequent kinase assay, one final wash with kinase buffer 
(25mM Tris, pH 7.5, 10mM MgCl2). Kinase assays were conducted in the presence of 
200μM ATP at 30°C for 20min with inactive MEK(K97R) (Millipore) as a substrate. The 
kinase reaction was terminated by adding sample buffer and boiling. Kinase activity was 
determined by immunoblotting for pMEK.
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siRNA knockdown
In order to selectively knock down p61BRAF(V600E) or full-length BRAF, siRNA 
duplexes were designed to target the junction between exons 3-9 (JC-1 and JC-2) or 
sequences within exons 4-8 (ex[4-8]-1 and ex[4-8]-2. The sequences are the following: 
JC-1: GGACAGUGGACUUGAUUAGUU, JC-2: AGGACAGUGGACUUGAUUAUU, 
ex[4-8]-1: ACUGAUAUUUCCUGGCUUAUU, ex[4-8]-2: 
CUGUCAAACAUGUGGUUAUUU. To knock down ARAF and CRAF we used siRNA 
pools. All siRNA duplexes were from Dharmacon and transfections were carried out with 
Lipofectamine 2000 (Invitrogen) at a final siRNA concentration of 50nM, according to the 
manufacturer’s instructions. 72 hours later, cells were either counted to estimate cell growth, 
or subjected to immunoblot analysis.
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Methods Summary
Vemurafenib20 (PLX4032) was obtained from Plexxikon Inc. PD0325901 was 
synthesized in the MSKCC Organic Synthesis Core Facility by O. Ouerfelli. Flag-tagged 
BRAF constructs have been described previously4. All other plasmids were created using 
standard cloning methods, with pcDNA3.1 (Invitrogen) as a vector. Mutations were 
introduced using the site-directed Mutagenesis Kit (Stratagene). The C1-5 vemurafenib-
resistant cells were generated by continuous exposure of parental SKMEL-239 cells to 
2μM of drug until the emergence of resistant colonies. Single cell cloning was then 
performed prior to biological characterization.
For cDNA preparation, the Superscript III First-Strand Synthesis kit (Invitrogen) was 
used. Sanger sequencing of the products was performed by Genewiz. For qPCR analysis, 
cDNA synthesis was carried out with the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). qPCR was performed with the iQ SYBR Green RT-PCR Super 
Mix (BioRad) and the C1000 Thermal Cycler (BioRad). The comparative Ct method was 
employed to quantify transcripts and delta Ct was measured in triplicate. Sequences of all 
primers used are available upon request.
Melanoma tumor specimens from patients treated with vemurafenib were collected on an 
IRB-approved protocols and were flash frozen immediately after resection or biopsy. To 
determine tumor content, 5 μm sections were cut, stained with hematoxylin and eosin, 
and scored by a pathologist. If the specimen had >70% tumor content (excluding 
necrosis), the remainder of the frozen tumor was homogenized using a Bullet Blender 
(Next Advance, Inc.) with 0.9-2 mm stainless steel beads for 5 min at a speed setting of 
10. RNA was then extracted from the tumor homogenate using the RNeasy Mini Kit 
(Invitrogen) and quantified.
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Figure 1. Resistance to the RAF inhibitor vemurafenib (PLX4032) is associated with failure of 
the drug to inhibit ERK signaling
a. Vemurafenib IC50 curves (at 5 days) for the SKMEL-239 parental cell line and five 
vemurafenib-resistant clones. b. Effects of 2μM vemurafenib on ERK signaling in parental 
(Par) and resistant clones (C1-5). c. Western blot for components of the ERK and AKT 
signaling pathways in parental and resistant clones (2μM PLX4032/24 hours). d. Dose-
response of pMEK and pERK downregulation at 1 hour to increasing concentrations of 
vemurafenib in parental and two representative resistant clones (C3 and C5). e. Graphic 
representation of the chemiluminescent signal intensities from 1d and IC50s for inhibition of 
MEK phosphorylation by vemurafenib in the parental and C3 and C5 clones.
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Figure 2. A BRAF(V600E) variant that lacks exons 4-8 is resistant to the RAF inhibitor 
vemurafenib
a. PCR analysis of BRAF in cDNA from parental (P) and C3 cells. Sequencing of the 1.7kb 
product expressed in the C3 clones but not in parental cells revealed an in frame deletion of 
five exons (4-8) in cis with the V600E mutation. Abbreviations: CR1: Conserved Region 1, 
CR2: Conserved Region 2, CR3: Conserved Region 3, RBD: RAS-binding domain, CRD: 
Cystine-Rich Domain. b. Full length wild-type BRAF and the 1.7kb/61kd splice variant of 
BRAF(V600E) were expressed in 293H cells. The effect of vemurafenib (2μM for 1 hour) 
on ERK signaling in the presence of p61BRAF(V600E) was analyzed by western blot for 
pMEK and pERK. c. To compare levels of dimerization, 293H cells co-expressing FLAG 
tagged and V5-tagged p61BRAF(V600E), full length BRAF(V600E) and the corresponding 
dimerization-deficient mutants p61BRAF(V600E/R509H) and BRAF(V600E/R509H) were 
lysed followed by immunoprecipitation with FLAG antibody. Western blotting with V5 or 
FLAG antibodies was performed as indicated. d. Comparison of MEK/ERK activation and 
sensitivity of ERK signaling to vemurafenib (2μM for 1 hour) in 293H cells expressing 
either Flag-tagged BRAF(V600E) or the dimerization mutant Flag-tagged BRAF(V600E/
R509H). e. Constructs expressing V5-tagged BRAF(V600E), p61BRAF(V600E) or the 
dimerization mutant p61BRAF(V600E/R509H) were transfected into 293H cells and treated 
with DMSO or 2μM vemurafenib for 1 hour.
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Figure 3. Identification of splice variants of BRAF(V600E) in human tumors resistant to 
vemurafenib
a. PCR analysis of cDNA derived from tumor samples from patients treated with 
vemurafenib. In samples with only one band (full-length BRAF), both BRAF(V600E) and 
wild-type BRAF (1+2) were detected. In resistant tumor samples expressing shorter 
transcripts, the shorter transcript was a splicing variant of BRAF(V600E) (3, 4, 5). The 
figure shows samples from three patients with acquired resistance to PLX4032: baseline (B) 
and disease progression (DP) samples from patient 1 and post-treatment samples from 
patients 11 and 12. A tumor sample from a patient with de novo resistance to vemurafenib 
(patient 20) is also shown. The intermediate band in samples expressing splicing variants 
(Pts 1, 11, 12) is an artifact of the PCR reaction resulting from switching between two very 
similar templates. Representative Sanger sequencing traces showing the junction between 
exons 3 and 11 in the DP sample from patient 1 compared to the full-length transcript 
derived from the baseline pre-treatment sample. b. As in A, baseline (B) and disease 
progression (DP) samples from a patient with an exon 2-10 deletion. RNA/cDNA levels of 
the exon 2-10 deletion were determined by qPCR using an exon 1/11 junction primer. The 
data are shown as the average of duplicates and expressed as relative levels between patient-
matched samples c. Exon organization of the splicing variants found in tumors from six 
patients that initially responded and then progressed on vemurafenib.
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